Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: A meta-analysis

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 17, 2013, Pages 2383-2389

  Wang, Y X ^a   Hu, D ^b   Yan, X ^a  

^a ZHENGZHOU PEOPLE S HOSPITAL   (China)

^b Institute of Infectious Disease   (China)

Author keywords

Cyfra 21 1; Meta analysis; Squamous cell carcinoma

Indexed keywords

CYTOKERATIN 19 FRAGMENT;

AREA UNDER THE CURVE; ARTICLE; DATA EXTRACTION; DIAGNOSTIC ACCURACY; ELECTROCHEMILUMINESCENT IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMMUNOASSAY; IMMUNORADIOMETRIC ASSAY; META ANALYSIS; QUALITY CONTROL; RANDOMIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANTIGENS, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; KERATIN-19; NEOPLASMS, SQUAMOUS CELL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84884244055     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. DE LUIS DA, IZAOLA O, CUELLAR L, TERROBA MC, DE LA FUENTE B, CABEZAS G. A randomized clinical trial with two doses of a omega 3 fatty acids oral and arginine enhanced formula in clinical and biochemical parameters of head and neck cancer ambulatory patients. Eur Rev Med Pharmacol Sci 2013; 17: 1090-1094.
2. SCHÖDER H. Head and neck cancer. Nuclear Oncology 2013; 10: 269-295.
3. DE MELO FILHO MR, ROCHA BA, PIRES MB, FONSECA ES, DE FREITAS EM, MARTELLI JUNIOR H, SANTOS FB. Quality of life of patients with head and neck cancer. Braz J Otorhinolaryngol 2013; 79: 82-88.
4. LANGER CJ. Exploring biomarkers in head and neck cancer. Cancer 2012; 118: 3882-3892.
5. SADICK M, SCHOENBERG SO, HOERMANN K, SADICK H. Current oncologic concepts and emerging techniques for imaging of head and neck squamous cell cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg 2012; 11: Doc08.
6. SAWANT SS, ZINGDE SM, VAIDYA MM. Cytokeratin fragments in the serum: their utility for the management of oral cancer. Oral Oncol 2008; 44: 722-732.
7. WHITING PF, WESWOOD ME, RUTJES AW, REITSMA JB, BOSSUYT PN, KLEIJNEN J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9.
8. LEEFLANG MM, DEEKS JJ, GATSONIS C, BOSSUYT PM. Cochrane Diagnostic Test Accuracy Working Group. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008; 149: 889-897.
9. DEEKS JJ, MACASKILL P, IRWIG L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58: 882-893.
10. AYUDE D, GACIO G, PÁEZ DE LA CADENA M, PALLAS E, MARTÍNEZ-ZORZANO VS, DE CARLOS A, RODRÍGUEZBERROCAL FJ. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep 2003; 10: 1345-1350.
11. CÉRUSE P, RABILLOUD M, CHARRIÉ A, DUBREUIL C, DISANT F. Study of cyfra 21-1, a tumor marker, in head and neck squamous cell carcinoma. Ann Otol Rhinol Laryngol 2005; 114: 768-776.
12. DENG YF, CHEN P, LIN YZ, LE JZ, WU XL, YU MQ, ZHUANG PY, GAO MH. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma. J Laryngol Otol 2003; 117: 190-194.
13. DOWECK I, BARAK M, GREENBERG E, URI N, KELLNER J, LURIE M, GRUENER N. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg 1995; 121: 177-181.
14. ELEFTHERIADOU A, CHALASTRAS T, FEREKIDOU E, KYRIOU L, YIOTAKIS I, PAPPAS Z, FEREKIDIS E, KANDILOROS D. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx. Anticancer Res 2006; 26: 2493-2497.
15. GOUMAS PD, MASTRONIKOLIS NS, MASTORAKOU AN, VASSILAKOS PJ, NIKIFORIDIS GC. Evaluation of TATI and CYFRA 21-1 in patients with head and neck squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 1997; 59: 106-114.
16. INAL E, LAÇIN M, ASAL K, CEYLAN A, KÖYBA IO LU A, ILERI F, USLU SS. The significance of ferritin, lipidassociated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck. Kulak Burun Bogaz Ihtis Derg 2004; 12: 23-30.
17. KANDILOROS D, ELEFTHERIADOU A, CHALASTRAS T, KYRIOU L, YIOTAKIS I, FEREKIDIS E. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Med Oncol 2006; 23: 463-470.
18. LEE JK, HSIEH JF, TSAI SC, HO YJ, SUN SS, KAO CH. Comparison of CYFRA 21-1 and squamous cell carcinoma antigen in detecting nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2001; 110: 775-778.
19. NAGLER RM, BARAK M, PELED M, BEN-ARYEH H, FILATOV M, LAUFER D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999; 85: 1018-1125.
20. WOLLENBERG B, JAN V, SCHMIT UM, HOFMANN K, STIEBER P, FATEH-MOGHADAM A. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer. Anticancer Res 1996; 16: 3117-3124.
21. YEN TC, LIN WY, KAO CH, CHENG KY, WANG SJ. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci 1998; 23: 82-86.
22. ZHONG LP, ZHU HG, ZHANG CP, CHEN WT, ZHANG ZY. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2007; 36: 230-234.
23. JONES CM, ATHANASIOU T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg 2005; 79: 16-20.
24. KANDILOROS D, ELEFTHERIADOU A, CHALASTRAS T, KYRIOU L, YIOTAKIS I, FEREKIDIS E. Prospective study of a panel of tumor markers as prognostic factors in patients with squamous cell carcinoma of head and neck. Med Oncol 2006; 23: 463-470.
25. AL-SHAGAHIN H, ALKOTYFAN K, MÜLLER HH, SESTERHENN AM, WERNER JA. Cyfra 21-1 as a serum tumor marker for follow-up of patients with laryngeal and hypopharyngeal squamous cell carcinoma. Anticancer Res 2009; 29: 3421-3425.